Sopan Pharmaceuticals Limited is set to open its Initial Public Offering (IPO) for the general public from 3rd Baishakh to 8th Baishakh, 2083. The company will issue 34,74,900 units IPO Shares to the general public at a face value of Rs. 100 per share. If the issue is not fully subscribed within the early closing period, the deadline will be extended until 17th Baishakh, 2083.
Sopan Pharmaceuticals has an issued capital of Rs. 1.71 Arba, of which 25 percent, or 42,90,000 units, has been allocated for the public offering. Out of the total shares, 10 percent (4,29,000 units) has been already issued to Nepali citizens working abroad, 4 percent (1,71,600 units) to employees, and 5 percent (2,14,500 units) to mutual funds. The remaining 34,74,900 units have been made available for the general public.
According to CARE Ratings Nepal Limited, the company holds an issuer rating of CARE-NP B (Is). The long-term bank facility rating stands at CARE-NP B, while the short-term rating is CARE-NP A4. These ratings indicate a high risk of default. The IPO is being managed by NMB Capital Limited. Investors can apply for a minimum of 10 units and a maximum of 11,000 units.
Applications for the IPO can be submitted through MeroShare and authorized financial institutions within the specified period.
About the Company
Sopan Pharmaceuticals Limited is a WHO-GMP, National GMP, and ISO 9001:2015 certified pharmaceutical company based in Lalitpur. Promoted by Sopan Multiple Company Limited, it began commercial production in 2078 B.S. and manufactures a range of medicines under strict cGMP standards. The company focuses on delivering safe, effective, and affordable pharmaceutical products, supported by strong capabilities in production, quality control, and research and development.
